We fund clinical trials for all types of cancers and prioritize only the most cutting-edge research that can help patients TODAY. Gateway invests in next generation patient-centric cancer research in order to drive transformational advances and breakthroughs in cancer treatment.
How Gateway is Unique:
Gateway focuses exclusively on patient-centered cancer research that improves treatment outcomes and restores the cancer patients’ quality of life.
Since its inception over 27 years ago, Gateway has funded over 180 innovative cancer research clinical trials. New trials are continuously added in a rolling grant application process.
A phase I and expanded imaging study of BLZ-100 in pediatric patients with primary brain tumors
A Phase II clinical trial to ameliorate symptoms of cognitive impairment in women treated with chemotherapy for breast cancer: the COGNUTRIN trial
Phase II: Study of pidilizumab in patients with diffuse large B-cell lymphoma following first remission
Gateway only invests in Phase I and Phase II human clinical trials where true innovation and transformational discoveries happen. Phase I and II clinical trials are severely underfunded, yet have the greatest patient impact in conquering cancer.
It costs just $16.56 per patient per day in a Gateway-funded cancer clinical trial. Will you help us fund another day of research? Fund one day, one week or more!
Michael Burton, Gateway for Cancer Research’s President and CEO, had the pleasure of speaking to Precision Oncology News about the emerging trend of “decentralized” cancer clinical trials in response to the impact of COVID-19 on clinical research. Click here to read more.